Bioterrorism

Testimony of Donald A. Henderson, MD, MPH, Founding Co-Director, Center for Civilian Biodefense Strategies, The Johns Hopkins University, Schools of Public Health and Medicine

Congress of the United States: U.S. Senate Veteran’s Affairs Committee, and the Appropriations Committee on Labor, Health and Human Services, Education and Related Services, March 16, 1999.

Good morning, Mr. Chairman and members of the Subcommittee:

I am Dr. D.A. Henderson, Professor of Epidemiology and International Health and Director of the Center for Civilian Biodefense Studies at Johns Hopkins University. My involvement in counter terrorism activities date back to 1990-93 when I served as a Science Advisor to President Bush. I sustained this interest during my tenure as Deputy Assistant Secretary and Senior Science Advisor in the Department of Health and Human Services. I continue to serve on a variety of consultant panels to the DOD and the intelligence community. This Committee has explicitly enunciated its own concerns with respect to bioterrorism. I share those concerns and am grateful for the support provided in helping us at Johns Hopkins to establish an academic center intended to catalyze a civilian planning and development program to deal with this vexing problem.

As this Committee is aware, this decade has been marked by escalating concerns about the threat of weapons of mass destruction. At first, discussions about the implications of this threat and its possible scenarios were confined primarily to those in the military, diplomatic, law enforcement and intelligence communities and to those concerned with arms reduction issues. Only recently have the civilian medical and public health communities begun to be engaged in examining the practical challenges posed by this threat.

The Unique Nature of the Biological Threat

Of the weapons of mass destruction, the biological ones are the most greatly feared but the country is least well prepared to deal with them. So far, virtually all federal efforts in strategic planning and training have been directed toward crisis management after a chemical release or an explosion. Should such an event occur, plans appropriately call for so-called “first responders”—fire, police, and emergency rescue workers—to proceed to the scene. There, with the FBI assuming lead responsibility, they are expected to stabilize the situation, to deal with casualties, to decontaminate, and to collect evidence for identification of a perpetrator. This is an important function and progress has been made in training and in developing such as the Metropolitan Medical Response Systems. Success in this effort must be attributed, in part, to the fact that spills or releases of hazardous materials, explosions, fires and other civil emergencies are not uncommon events.

A bioterrorist event presents an entirely different scenario, one that is alien to civil authorities. Epidemics of serious diseases such as are anticipated are wholly unknown to American cities. Unlike an explosive or chemical event, the bioweapons release would be silent and almost certainly undetected. The aerosol cloud would be invisible, odorless and tasteless. It would behave much like a gas in penetrating interior areas. No one would know until days or weeks later that anyone had been infected. Then, patients would begin appearing in emergency rooms and physicians’ offices with symptoms of
Responses Following a Bioweapons Attack

Special measures would be needed for patient diagnosis, care and hospitalization, for obtaining laboratory confirmation regarding the identity of microbes unknown to most laboratories, for providing vaccine and perhaps antibiotics to large portions of the population, and for identifying and possibly quarantining patients. Trained epidemiologists would be needed to identify where and when infection had occurred, so as to identify how and by whom it may have been spread. Public health administrators would be challenged to undertake emergency management of a problem alien to their experience, in a public environment where epidemics of pestilential disease are unknown, and in an environment where the potential for panic is high.

In brief, the personnel that are required, the skills that they must have and the strategies to be employed could hardly be more different. The prevailing assumptions that chemical and biological threats are generically so similar that they can be readily handled by multi-purpose ‘chembio’ experts is as patently ridiculous as to assume that the athletes playing on the Washington Redskins football team would be interchangeable with the Baltimore Orioles baseball club.

First responders to a biological weapons incident are emergency room physicians and nurses, family physicians, infectious disease specialists, infection control practitioners, epidemiologists, hospital and public health administrators, and laboratory experts. Until very recently, none of these groups had been meaningfully involved in assessing risks, nor in planning for appropriate civilian responses, nor in training, nor in defining research and development needs.

The National Initiative

I was extremely pleased last year when the Committee took cognizance of these practical challenges in coping with bioterrorism and appropriated to HHS for FY99, the sum of $133 million of which $51 million is intended for an emergency stockpile of antibiotics and vaccines. Other funds were allocated to the CDC, primarily for planning purposes, for the strengthening of the infectious disease surveillance network and for enhancing the capacity of federal and state laboratories. This was an important but still modest sum of money, considering the needs of a fragile public health infrastructure extending over 50 states and at least 120 major cities but it is an important beginning.

The provision of funds to HHS is consonant with the belief that one of the most critical elements for coping with bioterrorism is to strengthen the public health and infectious disease infrastructure. An augmented full-time cadre of professionals at the state and local level would represent, for biological weapons, a counterpart to the National Guard Rapid Assessment and Initial Detection Teams for chemical weapons. However, the augmented capabilities to deal with a bioterrorist event would not be on a standby status to be employed only in the case of an emergency. Rather, they would simultaneously serve to strengthen efforts directed toward dealing with such as new and emerging infections and food-borne diseases.

The sum of $1 million was identified for the Johns Hopkins Civilian Biodefense Studies Center. With these funds, a working group comprised of experts from federal, state and local institutions as well as academia have undertaken comprehensive reviews to identify the organisms that pose the most serious threats and that warrant special training of personnel in their identification and control and, as necessary, the development of relevant stockpiles of vaccines and antibiotics.

Two organisms in particular were identified as being of exceptional concern—smallpox and anthrax. Both are associated with high case fatality rates when dispersed as an aerosol. For smallpox, it is 30%; for anthrax, above 80%. Both have other advantages in that they can be grown reasonably easily and in large quantities and are sturdy organisms that are resistant to destruction. They are thus especially suited to aerosol dissemination to reach large areas and numbers of people.
The working group supported the view that reserve stockpiles both of anthrax and smallpox vaccines should be produced and that a stockpile of antibiotics should be created to deal with anthrax. The group believed that the possible development of second generation vaccines for both diseases should be explored as a matter of urgency. Documents setting forth the consensus views of these experts should be published in a major national publication within the next few months. Other documents detailing the threat and response for at least four other agents will follow.

Over the past year, personnel from the Hopkins Center have made more than 50 presentations, on the request of professional organizations and hospitals, to acquaint them with the realities of the threat of bioterrorism and to discuss initiatives that need to be taken. On 16-17 February, a National Symposium, sponsored by the Hopkins Center, HHS and 12 other sponsoring organizations, took place in Washington. It was the first of its kind directed to a public health and medical audience. The response was so great that registration had to be closed 10 days before the Symposium convened. At this time, I believe it is reasonable to conclude that there is a markedly heightened concern and desire on the part of the medical and public health community to take a far more active role in the nation’s preparedness.

**A Look to the Future**

Biologists, especially those in medicine and public health, are as critical to confronting the problems posed by biological weapons as are physicists in dealing with nuclear threats and chemists with chemical weapons. There is a need to expand the discussion regarding issues both at national and local levels, to recruit the interest and commitment of scientists in devising strategy, in undertaking needed research and in the complex planning process which is needed to blend together the very diverse array of institutions, both public and private in coherent local, state and federal plans.

Plans for dealing with large numbers of patients, including those who require isolation will have to be elaborated on a regional basis and plans developed for emergency care facilities, for decontamination procedures, for dispensing rapidly large quantities of vaccine and antibiotics, for rapid and secure communications, for informing the media in a timely manner, for provision of mental health services and for emergency mortuaries.

Developing the experts and expertise will require a major educational effort, given the variety of specialists that are needed and the now virtual absence of knowledgeable and experienced specialists. There is a need to train primary care physicians and emergency room personnel in early recognition of the most important disease threats. Infectious disease specialists and hospital epidemiologists must also become versed in case recognition and in steps to take if a suspicious case is detected. There is a need for trained laboratory directors and key staff in laboratories with designated responsibilities for lab diagnoses. Moreover, state and local health officers and epidemiologists require training in, among other things, detection, surveillance, and management of epidemic disease. Such an effort will require the full participation of professional organizations as well as those in the public sector and in academia.

Last but not least, it will be important to recruit the help of the medical and public health community in longer term measures that may prevent acts of terrorism. This would include strengthening the provisions of the Biological Weapons Convention Treaty and expanding our intelligence capabilities so as to anticipate and perhaps interdict terrorists. The fostering of international cooperative research programs to encourage openness and dialogue as is now being done with Russian laboratories is also important.

The possible role of the medical community in educating peoples and policymakers everywhere about the dread realities of bioterrorism has also been proposed as a parallel effort to an earlier initiative that proved so effective in clarifying the disastrous consequences of a nuclear war.